Kirkland Represents Sagent Pharmaceuticals on its Acquisition by Nichi-Iko Pharmaceutical for Approximately $750 Million

Kirkland & Ellis LLP advised Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, on its acquisition by Nichi-Iko Pharmaceutical Co., Ltd (TSE: 4541), the largest generic drug manufacturer in Japan by sales. The transaction is valued at approximately $750 million. Under the terms of the agreement, Nichi-Iko will commence a tender offer for the shares by the end of July, and the parties expect the transaction to close during the third quarter. Kirkland previously represented Sagent in its initial public offering for listing on the NASDAQ in April 2011. The full release is available here.

The Kirkland team was led by corporate partners George Stamas, William Sorabella and Alexander Fine and associates Adele Maloney Thomas and Claire James; and executive compensation partner Scott Price.